Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Biotechnology

Healthcare
$119.04 +3.57%

+$3.42 today

Market cap
$8.25B
Beta
1.92
P/E (TTM)
-33.3
EPS (TTM)
-$2.98
52W Low $60.80High $122.20

Volume 2.01M

Average 0.81M

RYTM Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM

Net Margin · Q3 FY2026 · quarter ended Sep 2026

Net margin widens to -44.9%

Net margin was -44.9% in Q3 FY2026, up 58.2 pp from a year earlier. On a trailing-twelve-month basis it was -69.0%, up 41.3 pp year over year. Over 3 fiscal years it widened by 662.6 pp.

Context

  • Net margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 13 analysts of -107.4% for the fiscal year ending Dec 2026, down from -103.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-44.9%+24.3 pp QoQ
Last fiscal yearDec 2025
-103.6%+96.7 pp YoY
LTMSep 2026
-69.0%+41.3 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+58.2 pp-96.1 pp-154.3 pp
1 year+96.7 pp-3.8 pp-100.5 pp
3 years+662.6 pp+118.7 pp-543.9 pp
5 years+140.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-103.6%
Year-over-year change
+96.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How RYTM compares with its peers on the latest reported figures

  • RYTM's LTM Sep 2026 net margin of -69.0% is the 4th highest of the 6 companies compared; the peer median is -61.3%.
  • Its year-over-year change of +41.3 pp is the 4th highest of 6, against a peer median of +205.5 pp.
  • Over three fiscal years its change of +662.6 pp compares with a peer median of +4.1 pp.
RYTM Competitors Peer median
Net Margin for RYTM and competitors
Company Period LTM level YoY 3-year change
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026-11.9% -28.8 pp+4.1 pp
PTNPalatin Technologies, Inc.LTM Mar 2026-48.5% +6616.6 pp—
SEPNSepterna, Inc.LTM Sep 2026-61.3% +205.5 pp—
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026-69.0% +41.3 pp+662.6 pp
MAZEMaze Therapeutics, Inc.LTM Mar 2026-612.7% -643.7 pp—
BIOABioAge Labs, Inc.LTM Mar 2026-871.8% +4024.5 pp—
BLTEBelite Bio, IncFY2025— ——
VKTXViking Therapeutics, Inc.FY2025— ——
MBXMBX Biosciences, Inc. Common StockFY2025— ——
GPCRStructure Therapeutics Inc.FY2025— ——
BMEABiomea Fusion, Inc.FY2025— ——
Peer median (excluding RYTM) -61.3%+205.5 pp+4.1 pp

Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.15M23.64M77.43M130.13M189.76M
Cost of Revenue599K2.13M9.3M13.37M19.49M
Gross Profit2.56M21.51M68.13M116.76M170.27M
Gross Margin81.0%91.0%88.0%89.7%89.7%
Research & Development104.13M108.63M134.95M237.96M167.34M
Selling, General & Admin68.49M92.03M117.53M144.3M194.94M
Operating Expenses172.61M200.66M252.48M382.26M362.28M
Depreciation & Amortization1.16M1.67M1.76M1.56M1.34M
EBITDA(68.45M)(174.25M)(168.46M)(238.09M)(174.12M)
EBITDA Margin-2170.4%-737.1%-217.6%-183.0%-91.8%
Operating Income(170.06M)(179.16M)(184.36M)(265.5M)(192.02M)
Operating Margin-5391.9%-757.9%-238.1%-204.0%-101.2%
Interest Income447K4.03M13.95M14.71M15.29M
Interest Expense05.2M13.89M20.6M20.58M
Other Income / Expenses100.45M(1.96M)243K5.25M(4.03M)
Income Before Tax(69.61M)(181.12M)(184.11M)(260.26M)(196.04M)
Pre-Tax Margin-2207.1%-766.2%-237.8%-200.0%-103.3%
Income Tax Expense00564K346K497K
Net Income(69.61M)(181.12M)(184.68M)(260.6M)(196.54M)
Net Margin-2207.1%-766.2%-238.5%-200.3%-103.6%
EPS (Basic)(1.37)(3.51)(3.20)(4.34)(3.11)
EPS (Diluted)(1.37)(3.51)(3.20)(4.34)(3.11)
Weighted Avg Shares49.6M52.12M57.67M61M64.98M
Weighted Avg Shares (Diluted)49.6M52.12M57.67M61M64.98M

Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Intrinsic Alpha fair value

Locked

Current Price

$119.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.